Abstract 15810: Pcsk9, Thromboxane and Cardiovacular Events in Atrial Fibrillation

Introduction: Patients with atrial fibrillation (AF) display enhanced platelet activation but the underlying mechanism is still unclear. Hypothesis: We investigated 1) the association between soluble PCSK9 and CVEs in patients with AF, 2) the relationship between soluble PCSK9 and 11-dehydro-thromboxane (Tx) B2 ,a realiable marker product of platelet activation. Methods: Prospective single-center cohort study including 907 AF patients treated with AVK and followed-up for about 40 months (3865 patients/year) to assess CVEs,. At admission, plasma PCSK9 and urinary excretion of 11-dehydro-TxB2 (n=852) were measured. Results: Mean age was 73.5±8.2 years, and 43.0% were women. The total number CVEs registered during follow-up was 179 (4.6%/years). By maximizing the hazard ratio (HR), we found that >2600 pg/ml was the best-cut-off value of PCSK9 for CVEs (HR 2.8, p 2600 pg/ml (HR:2.536, p<0.001], age (HR:1.083, p<0.001), female sex (HR:0.723, p=0....